Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.

Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...

The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...

Shares of Hims Hers Health Inc (NYSE:HIMS) fell more than 3% early Tuesday before paring losses to around 0.2% in afternoon trade, after rising legal risks and a data disclosure drove swings in ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.